Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Endo Int'l Plc (ENDP)

Endo Int'l Plc (ENDP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,446,831
  • Shares Outstanding, K 226,776
  • Annual Sales, $ 2,947 M
  • Annual Income, $ -1,031,470 K
  • 60-Month Beta 1.41
  • Price/Sales 0.49
  • Price/Cash Flow 0.96
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.57
  • Number of Estimates 7
  • High Estimate 0.59
  • Low Estimate 0.55
  • Prior Year 0.75
  • Growth Rate Est. (year over year) -24.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.28 +49.07%
on 12/30/19
6.54 -2.45%
on 01/21/20
+1.40 (+28.11%)
since 12/20/19
3-Month
3.98 +60.30%
on 11/12/19
6.54 -2.45%
on 01/21/20
+1.73 (+37.20%)
since 10/21/19
52-Week
1.97 +223.86%
on 09/05/19
12.49 -48.92%
on 02/28/19
-3.32 (-34.23%)
since 01/18/19

Most Recent Stories

More News
J&J's $8B Jury Award in Risperdal Case Cut to $6.8M by Judge

A Philadelphia judge slashes J&J's (JNJ) punitive damages in a lawsuit, which claims that the company did not warm men that they could grow breasts by using its antipsychotic drug, Risperdal.

JNJ : 149.27 (+0.07%)
ENDP : 6.38 (+5.63%)
TEVA : 10.02 (-1.76%)
MNK : 6.04 (+16.15%)
Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

AGN : 192.58 (-0.05%)
ENDP : 6.38 (+5.63%)
TEVA : 10.02 (-1.76%)
MNK : 6.04 (+16.15%)
Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million

Endo International plc today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement with the...

ENDP : 6.38 (+5.63%)
Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million

Endo International plc (NASDAQ: ENDP) today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. (collectively, the "Settling Parties") have executed a Settlement Agreement...

ENDP : 6.38 (+5.63%)
Interesting ENDP Put And Call Options For February 14th

Investors in Endo International plc saw new options begin trading today, for the February 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ENDP options chain...

ENDP : 6.38 (+5.63%)
Will J&J be Able to Overcome Its Legal Troubles in 2020?

Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

JNJ : 149.27 (+0.07%)
ENDP : 6.38 (+5.63%)
TEVA : 10.02 (-1.76%)
MNK : 6.04 (+16.15%)
Implied Volatility Surging for Endo (ENDP) Stock Options

Investors need to pay close attention to Endo (ENDP) stock based on the movements in the options market lately.

ENDP : 6.38 (+5.63%)
Prostate Cancer Market Overview, Size, Share, Analysis, Value and Global Industry 2019-2024

AZN : 50.80 (-1.03%)
ENDP : 6.38 (+5.63%)
OBMP : 0.1500 (unch)
PGNX : 4.64 (-1.07%)
TKAI : 0.61 (-4.69%)
PostOperative Pain Management Market is highly promising expected to witness a notable CAGR of 5.4% by 2023 – MRFR

BAX : 91.07 (+1.49%)
LLY : 140.91 (+0.95%)
ENDP : 6.38 (+5.63%)
GSK : 47.50 (-0.81%)
TEVA : 10.02 (-1.76%)
VRX.TO : 30.80 (-3.33%)
Endo to Participate at J.P. Morgan Healthcare Conference

Endo International plc (NASDAQ: ENDP) announced today that members of management will present at the J.P. Morgan Healthcare Conference in San Francisco, California on Monday, January 13, 2020 at 3:30 p.m....

ENDP : 6.38 (+5.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ENDP with:

Business Summary

Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova,...

See More

Key Turning Points

2nd Resistance Point 6.87
1st Resistance Point 6.63
Last Price 6.38
1st Support Level 6.05
2nd Support Level 5.71

See More

52-Week High 12.49
Fibonacci 61.8% 8.47
Fibonacci 50% 7.23
Last Price 6.38
Fibonacci 38.2% 5.99
52-Week Low 1.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar